Spectranetics Q4 net loss widens
The net loss for 2008 was $4 million, or $0.12 per share, inclusive of after-tax IPR&D costs of $2.4 million, or $0.08 per share, compared with net income
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.